Dr Lal PathLabs

February 08, 2018

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Press Release for Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2017

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2017.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited

Dr Lal PathLabs Limited

Rajat Kalra
Company Secretary & Legal Head

Encl: As above

For Immediate Release **Feb 8, 2018**

Dr. Lal PathLabs Limited records revenue growth of 26.6% in Q3FY2017-18

New Delhi, India, Feb 8, 2018 – Dr. Lal PathLabs Limited (referred to as the "Company"; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended December 31, 2017

Consolidated Performance Highlights: Q3FY2017-18 vs. Q3FY2016-17
Revenue growth: 26.6% Normalised EBITDA at Rs 596 mn, PBT at Rs 555 mn
Normalised EBITDA margins healthy at 22.7% and
PBT margin at 21.1%

- Operating Revenue increased by 26.6% in Q3 to Rs. 2627 million vs Rs 2075 million in the previous year same quarter. Underlying volume growth is 26.1% during the quarter. For the nine month period to December 2017 revenue grew 14.1% to Rs 7901 million with volume growing 13.2%
- Normalised EBITDA in Q3FY18 grew 22.5% to Rs.596 million from Rs 487 million in the same quarter last year, after adjusting for RSU and other stock based compensation costs. Nine months YTD normalised EBITDA grew 8.6% to Rs 2083 mn
- EBITDA Margin was consistent at 22.7% for Q3 FY18 vs 23.5% in Q3 FY17 and for the nine months period the EBITDA margin was 26.4%
- PBT was Rs 555 mn in Q3 vs Rs 472 mn in Q3 last year while nine months YTD PBT increased to Rs 1993 mn from RS 1880 mn
- Profit after Tax in Q3FY18 at Rs. 364 million compares with Rs 309 million in Q3 last year. YTD nine months PAT at Rs 1319.5 mn grew 6.7%

Financial Overview (Consolidated) in Rs mn

Particulars (Rs Mn)	YTD DEC 17	YTD DEC 16	*Gr %*	DQ FY 17	DQ FY 16	*Gr %*
Total Revenue	**7,900.6**	**6,924.7**	***14.1%***	**2,627.0**	**2,074.6**	***26.6%***
Total Expenditure	5,901.0	5,048.3		2,061.0	1,603.6	
EBITDA	**1,999.6**	**1,876.4**	***6.6%***	**566.0**	**471.1**	***20.2%***
RSU and stock based comp. cost	83.6	42.5		29.9	15.6	
Normalised EBITDA excl RSU	**2,083.2**	**1,918.9**	***8.6%***	**595.9**	**486.6**	***22.5%***
Normalised Margins	*26.4%*	*27.7%*		*22.7%*	*23.5%*	
Other income incl interest	223.0	208.0	*7.2%*	71.0	74.2	*-4.3%*
PBT	**1,993.4**	**1,879.9**	***6.0%***	**555.0**	**472.0**	***17.6%***
Margins	*25.2%*	*27.1%*		*21.1%*	*22.7%*	
PAT	**1,319.5**	**1,237.0**	***6.7%***	**364.0**	**309.3**	**17.7%**
Margins	*16.7%*	*17.9%*		*13.9%*	*14.9%*	
EPS (Basic)	**16.01**	**15.13**	***5.8%***	**4.40**	**3.78**	***16.4%***
EPS (Diluted)	**16.00**	**15.03**	***6.5%***	**4.40**	**3.75**	***17.3%***

Figures have been recast as per Ind AS requirements

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Dr. Lal PathLabs has built a national, "hub and spoke" network that includes its National Reference Laboratory in New Delhi, 188 other clinical laboratories, 1,759 patient service centers and 5,021 pickup points as of March 31, 2017. Their customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Dilip Bidani
Dr. Lal PathLabs Limited
+91 124 3016500
cfo@lalpathlabs.com

Aparna Agarwal
Adfactors PR
+91 9811177405
aparna.agarwal@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.